Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. Issue 4 (12th July 2016)

• Record Type: Journal Article
• Authors: Chisini, Marta; Stefanizzi, Caterina; Ceglie, Teresa; Raponi, Sara; Vozella, Federico; Colafigli, Gioia; Salaroli, Adriano; D'Angiò, Mariella; Mancini, Marco; Diverio, Daniela; Breccia, Massimo; Mancini, Francesca; Minotti, Clara; Trisolini, Silvia; Capria, Saveria; Testi, Anna Maria; Guarini, Anna; Latagliata, Roberto; De Propris, Maria Stefania; Foà, Robin
• Is Part Of: Hematological oncology. Volume 35:Issue 4(2017:Dec.)
• Page Start: 804
• Page End: 809
• Publication Date: 2016-07-12
• Subjects: acute myeloid leukemia -- CD15 -- complete remission -- immunophenotype -- prognosis; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2331
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: The prognostic role of CD15 in acute myeloid leukemia (AML) has been tested in different studies with conflicting results. To address this issue, we retrospectively evaluated a cohort of 460 AML patients of all ages with the exclusion of acute promyelocytic leukemia (M/F 243/217, median age 50.6 years [range 0.9‐81.2]) intensively treated at our institute between January 1999 and December 2010. CD15 positivity was found in 171 of 406 evaluable patients (42.1%). Complete remission (CR) was achieved by 334 patients (72.6%), while 82 (17.8%) were resistant and 44 (9.6%) died during induction: the median CR duration was 15.5 months (range 0.6‐176.0), with 2‐year disease‐free survival rate of 45.1% (95% confidence interval 39.6‐50.6). The median overall survival was 14.4 months (range 0.3‐177.0), with 2‐year overall survival rate of 42.2% (95% confidence interval 37.5‐46.9). At univariate analysis for CR achievement, age < 60 years ( P < .001), World Health Organization classification ( P = .045), low‐risk karyotype ( P < .001), no high‐risk karyotype ( P = .006), positivity for AML‐ETO ( P = .004)/CBFβ‐MYH11 ( P = .003)/CD15 ( P = .006)/CD11b ( P = .013), negativity for FLT3‐ITD ( P = .001), Hb > 8 g/dL ( P = .020), and white blood cell < 50 × 10 9 /L ( P = .034) had a favorable impact. At a multivariate logistic regression model, CD15 positivity ( P = .002), age < 60 years ( P = .008), white blood cell < 50 × 10 9 /L ( P = .017), and low‐risk/no high‐risk karyotype ( P = .026/ P = .025) retained an independent prognostic role on CR achievement. The baseline assessment of CD15 positivity appears to have a role in the risk evaluation for CR achievement in AML patients undergoing intensive chemotherapy and should be assessed in prospective studies together with other clinical and biologic features already reported.